



## **Ventripoint Welcomes Bart Hendriks as New Strategic Partnerships Executive to Accelerate European and Global Sales**

### **For Immediate Release**

**Toronto, Ontario – February 13, 2024** – Ventripoint Diagnostics Ltd. ("**Ventripoint**" or the "**Company**"), (TSXV:VPT; OTC:VPTDF) is delighted to welcome Bart Hendriks as the company's new Strategic Partnerships Executive, to accelerate adoption of Ventripoint's AI-powered, heart-scanning technology by hospitals and clinics in Europe and around the world.

A seasoned professional in the MedTech artificial intelligence field, Bart brings a wealth of experience from his tenure in various leadership capacities, including CEO and Founder of innovative ventures in medical technology, diagnostics, and AI-driven clinical applications.

Based in The Netherlands, Bart will focus on expanding European and global sales of Ventripoint's technology, which analyses ultrasound scans and provides MRI-quality measurements of the heart, at the fraction of the cost and time and trauma of MRIs.

"Bart has excelled in global sales and marketing management, strategic partner development, change management, and has shown adeptness in mergers and acquisitions, deal structuring, negotiations and team leadership," said Ventripoint's Interim CEO Hugh MacNaught. "Our focus is now commercialization of Ventripoint's technology. Bart's track record includes successfully closing multiple funding rounds, securing strategic contracts, and driving substantial revenue growth across different organizations. "

Hendriks' role begins immediately. His full bio is [here](#).

Added Hendriks: "Ventripoint's technology is unique, offering a revolutionary mix of precision, efficiency, and user-friendliness in cardiac diagnostics using artificial intelligence. This cutting-edge tool is set to alter the paradigm of heart health management, making cardiac scans more accessible and effective for patients across the globe, and offers a portable, inexpensive alternative to MRIs that takes only minutes."

### **For further information, please contact:**

Jonathan Robinson CFA

[JRobinson@oakhillfinancial.ca](mailto:JRobinson@oakhillfinancial.ca)

(416) 669-1001



Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

### **About Ventripoint Diagnostics Ltd.**

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

### **Forward Looking Statements**

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at [www.sedar.com](http://www.sedar.com). Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether because of new information, future events or otherwise, unless so required by applicable securities laws.